Home / Market News / $CYTK
benzinga Corporate Catalyst Impact 55/100 ● neutral

HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target

Oct 19, 2026, 2:22 PM UTC · Primary ticker $CYTK

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating and a $140 price target for Cytokinetics. This indicates continued analyst confidence in the company's prospects, which could provide some positive sentiment for investors.

This 8-K filing discloses that HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating for Cytokinetics (CYTK) and maintained a $140 price target. This is a routine update from an analyst and signifies continued confidence in the company's valuation and future performance. While not a new development, it reinforces existing positive sentiment and could provide a minor short-term boost or stability to the stock as it confirms analyst support. For traders, this reiteration suggests that the analyst's previous investment thesis remains intact, potentially reducing downside risk in the short term, but it doesn't introduce new catalysts for significant upward movement.

$CYTK positive Analyst reiterates Buy rating and price target
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.